← All trials
NCT01215357
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- May 1, 2012
- Completion date
- Aug 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Psyadon PharmaLead sponsor
- University of California, Los AngelesOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- University of MinnesotaOverall official - principal investigator
- University of IowaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.